Urothelial Cancer Drugs Market Size, Growth, and Analysis Report to 2029 | DataMIntelligence

DataM Intelligence
Global Urothelial Cancer Drugs Market is expected to grow at a high CAGR of 21.1% during the forecasting period (2022-2029).

Market Overview:

Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous bladder tumor that can spread to other parts of the body. The urothelium comprises the lining inside the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise the urothelial cells or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It comprises over 90% of all bladder cancers.

Market Size Growth Rate:

According to the DataM market research report, the global urothelial cancer drugs market size was valued at USD YY billion in 2021, it is projected to reach at USD YY billion by 2029, with growth at a CAGR of 21.2% over the forecast period 2022-2029.

Going forward, the global urothelial cancer drugs market is predicted to see growth because of the disease progression and high recurrence rates in patients with aggressive carcinoma in-situ (CIS) classification. In the near future, the global urothelial cancer drugs market would also be boosted with better therapies being approved by prominent drug regulatory organizations.

 

Download free sample @ https://www.datamintelligence.com/download-sample/urothelial-cancer-drugs-market

 

Market Drivers:

Several novel treatments are predicted to see approvals thereby further spelling revenue for the market. Already, TECENTRIQ and OPDIVO, which are the PD-L1 inhibitors, are set to impact the market dynamics positively with their approval by the US FDA. Better knowledge about tumor immunology will likely help drug to formulate more such effective therapies in the global urothelial cancer drugs market.

Market Restraints:

Increasing emergence of generic drugs along with high cost of expenditure in research and development activities which will likely to act as market restraints factor for the growth of the urothelial cancer drugs. Increasing cost of branded drugs along with side effects associated with chemotherapy such as mouth sores, diarrhoea, nausea and vomiting which will become the biggest and foremost challenge for the growth of the market.

Market Opportunities:

The development of clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) technology has shown potential to treat urothelial cancer. 

CRISPR technology can be used to discover the non-coding cancer genome. CRISPR is a family of DNA sequence found in the genomes of prokaryotic bacteria such as archaea. CRISPR-Cas9 changes the DNA sequences and messages by inserting a cut or break in the DNA. CRISPR-Cas9 uses specific proteins to convalesce mutations at genetic level. The technology has entered into clinical trials in the oncology space focused on reprogramming immune cells to the target and destroys tumor cells. CRISPR-Cas9 genome editing reduces the processing associated with the generation of cell line and animal models of cancer and complex generations. It can be employed to promptly engineer oncolytic viruses and immune cells for cancer therapeutic applications.

COVID-19 Impact Analysis:

The emergence of COVID-19 has had a profound impact on the urothelial cancer drugs market as well. As per the data provided by the National Health Services, England on ‘NHS Diagnostic Waiting Times and Activity Data’, 2020, stated that the healthcare services had been devastated, globally. As of August 2020, approximately 50.2% of patients in England for cystoscopy had to wait for at least six weeks compared to 9% in 2019. Thus, this delay in diagnosis impacted negatively on the therapeutic interventions as well, thereby, limiting the market studied.

Recent Developments in the Industry:

In 2019, Astellas Pharma announced permission of U.S. Food and Drug Administration for launch of PADCEV. This product helps in treatment of advanced urothelial cancer.

Market Segmentation:

As per the research analysis, the global urothelial cancer drugs market is segmented by type into Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma. By treatment into Chemotherapy, Immunotherapy. By distribution channel the market is further segmented into Hospital Pharmacies, Specialty Clinics, Cancer Institutes, Ambulatory Surgical Centers.

On the basis of treatment, the chemotherapy segment is estimated to grow at highest CAGR of XX% during the forecast period (2022-2029). Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of urothelial cancer cells. It works throughout the whole body to destroy and damage cancer cells spread to other parts of the body away from the original tumor. The chemotherapy product launches and approvals for urothelial cancer are expected to boost the market growth. For instance, in December 2019, the United States Food and Drug Administration approved Padcev (enfortumab vedotin-ejfv) developed by Astellas Pharma US Inc. and Seattle Genetics Inc. It has been indicated against the treatment of advanced urothelial cancer.

Furthermore, as per the results of ‘Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomized controlled trial’, published in March 2020, gemcitabine-platinum combination chemotherapy significantly improved the outcomes in patients suffering from upper tract urothelial carcinoma. Such studies are expected to aid the market growth in this segment.

Based on type, the squamous cell carcinoma segment accounted for the largest market share of around XX% in 2020 and expected to grow at a CAGR of XX% during the forecast period (2022-2029). About 5 out of every 100 (5%) bladder cancers are squamous cell cancers. It is usually invasive. Squamous cells are flat cells that make up the moist, skin-like tissues lining your body organs. This type of bladder cancer develops from these cells. It is more common in developing countries where a worm infection called bilharzia or schistosomiasis is widespread.

 

View full report @ https://www.datamintelligence.com/research-report/urothelial-cancer-drugs-market

 

Geographical Classification:

The global urothelial cancer drugs market is segmented into major regions including North America, Europe, South America, Asia Pacific, and Middle East and Africa.

North America Urothelial Cancer Drugs Market:

North America at present is a prominent contributor to revenue in the urothelial cancer drugs market. Though the market in the region is somewhat saturated and would likely rise at a slow pace in the next couple of years, it would still retain its key position. This is because of the exhaustive research on developing targeted therapies by well-established vendors domiciled in the region. Some of those are Merck and Pfizer. The U.S. is said to be mainly powering the growth in the North America urothelial cancer drugs market.  

The APAC and Europe region urothelial cancer drugs market is estimated to grow at a CAGR of YY % during the forecast period (2022-2029) to reach a market value of USD YY million by 2029. Germany and Japan in Europe and Asia Pacific, respectively are other major contributors to the global urothelial cancer drugs market. The presence of a sizeable proportion of the target population, high uptake of novel therapies, and several product launches lined up by vendors in the nations.

Competitive Analysis:

The urothelial cancer drug market is competitive. However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. Few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the urothelial cancer drugs market crowded with new products in the next couple of years.

Major Companies:

Some of the major key players in the market are Novartis AG, GlaxoSmithKline, Genentech, Bristol-Myers Squibb, Sanofi S.A., Eisai Co., Ltd., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., UroGen Pharma Ltd., Immunomedics, Inc., and others.

 

Trending Topic’s

CD Antigen Cancer Therapy Market

Kidney Cancer and Renal Cell Carcinoma Drugs Market

 

Additional Benefits Post Purchase:

1) Unlimited Analyst support for a period of 1 year. 

2) Any query with regards to the scope offered will be addressed within 24- 48 hours.

3) An excel sheet with market numbers will be provided separately.

The Full Report has the below insights: 

The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
Visualize the composition of the global urothelial cancer drugs market segmentation by type, treatment, distributional channel, and region highlighting the key commercial assets and players. 
By Type: Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma
By Treatment: Chemotherapy, Immunotherapy
By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Cancer Institutes, Ambulatory Surgical Centers
By Region: North America, South America, Europe, Asia Pacific and Middle East and Africa

Identify commercial opportunities in the global urothelial cancer drugs market by analyzing trends and co-development deals.
The report also covers data insights on various industry forces such as, porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis, reimbursement analysis and unmet needs etc.
Excel data sheet with thousands of data points of global urothelial cancer drugs market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.  
Product mapping in excel for the key product of all major market players
The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.  

 

About Us:

DataM Intelligence 4Market Research is a market intelligence platform which gives access to syndicated, customized reports and consulting to its clients at one place. As a firm with rich experience in research and consulting across multiple domains we are one stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed and food & beverages among others. Our platform has Insights on markets that uncover latest market research data that’s distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market by providing a complete view of the market with statistical forecasts. Our strategy centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/urothelial-cancer-drugs-market